MMSL 2022, 91(2):89-97 | DOI: 10.31482/mmsl.2021.038

COVID-19 AMONG A SAMPLE OF IRAQI PATIENTS WITH RHEUMATIC DISEASES: A MULTICENTER STUDYOriginal article

Faiq I. Gorial ORCID...1, Ali Abdulrahman Younis ORCID...2*, Ali Alkazzaz ORCID...3, Avin M. Arif Maroof ORCID...4, Taha Ahmad Qaradaghi5, Chiman Hasan Mahmood6, Mohammed H. ALosami1, Dina Shakir Yasiry7, Nabaa Ihsan Awadh ORCID...7, Marwa Moayad Younis8, Farah J. Mahdi9, Saad Waheed Mihan10, Nizar A. Jassim ORCID...1
1 Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
2 Department of Medicine, College of Medicine, University of Mosul, Mosul, Iraq
3 Department of Medicine, University of Babylon, Babylon, Iraq
4 Faculty of Health technology at Cihan University. Rizgary Teaching Hospital, Erbil, Iraq
5 Rheumatology section, Sulaymaniyah Internal Medicine Teaching Hospital, Sulaymaniyah, Iraq
6 Rheumatology Department, Shahid Hemn Teaching Hospital of Medicine, Sulaymaniyah, Iraq
7 Rheumatology Unit, Baghdad Teaching Hospital, Baghdad, Iraq
8 Rheumatology Unit, Al-Yarmouk Teaching Hospital, Baghdad, Iraq
9 Postgraduate student, Rheumatology Unit, Baghdad Teaching Hospital, Baghdad, Iraq
10 Basra Teaching Hospital, Basra, Iraq

Background: There are scarce data on disease characteristics and severity of coronavirus 2019(COVID - 19) among Iraqi patients with rheumatic diseases (RDs). In this study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among patients with RDs.

Methods: Between October 2020 and April 2021, rheumatic diseases (RDs) patients with COVID-19 were registered from different centres in Iraq. The patient's demographics, rheumatological history, COVID-19 symptoms, severity, and management, if any, their disease progress and outcome have been assessed. Binary logistic regression analysis was performed to determine predictors of disease severity.

Results: 253 patients were included in the study, and most were females. The commonest rheumatic disease was rheumatoid arthritis (RA), followed by systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) (95, 52 and 20 patients respectively). It has been found that 50.6% of patients had mild COVID-19, and 49.4% had moderate disease; 18% of patients required oxygen support, no patient was treated in hospital, and there was no reported death. Patients with moderate COVID-19 had significantly higher age than mild type (p= 0.022); with more BMI (p=0.03), more in the number of comorbidities (p<0.001), more steroids users (p=0.012), higher steroid dose (P=0.034), had longer steroid duration,   longer duration of conventional disease-modifying antirheumatic drugs (cDMARDs) (p=0.018), and biologic Disease-modifying Antirheumatic Drug (bDMARDs) in months (p=0.025). Increasing body mass index (BMI), duration of biological DMARDs use, and an increasing number of comorbidities were significant independent factors that increase the risk of having more severe COVID-19, (p<0.05).

Conclusion: COVID-19 infection rheumatic patients tend to have mild-moderate disease course; BMI, duration of biological DMARDs use, and many comorbidities were significant independent factors that increase the risk of having more severe COVID-19.

Keywords: SARS-CoV-2; COVID-19; DMARDs; rheumatic diseases; rheumatoid arthritis

Received: September 2, 2021; Revised: October 25, 2021; Accepted: November 5, 2021; Prepublished online: December 6, 2021; Published: June 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Gorial, F.I., Abdulrahman Younis, A., Alkazzaz, A., Arif Maroof, A.M., Qaradaghi, T.A., Mahmood, C.H., ... Jassim, N.A. (2022). COVID-19 AMONG A SAMPLE OF IRAQI PATIENTS WITH RHEUMATIC DISEASES: A MULTICENTER STUDY. MMSL91(2), 89-97. doi: 10.31482/mmsl.2021.038
Download citation

References

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. https://doi.org/10.1016/S0140-6736(20)30183-5 Go to original source... Go to PubMed...
  2. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65:533-46. https://doi.org/10.1007/s00038-020-01390-7(0123456789().,-volV)(0123456789,-().volV) Go to original source... Go to PubMed...
  3. Kastritis E, Kitas GD, Vassilopoulos D, et al. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int. 2020;40:1353-60. https://doi.org/10.1007/s00296-020-04629-x Go to original source... Go to PubMed...
  4. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38:337-42. Go to original source... Go to PubMed...
  5. World Health Organization. Clinical Management of COVID-19: Interim Guidance. World Health Organization; 2020:13-15.
  6. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80(7):930-942. doi:10.1136/annrheumdis-2020-219498 Go to original source... Go to PubMed...
  7. AI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients [published online ahead of print, 2020 Dec 2]. Ann Rheum Dis. 2020; 80(4):527-538. Go to original source... Go to PubMed...
  8. Alzahrani ZA, Alghamdi KA, Almaqati AS. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatol Int. 2021; 41(6):1097-1103. https://doi.org/10.1007/s00296-021-04857-9 Go to original source... Go to PubMed...
  9. Hasseli R, Mueller-Ladner U, Schmeiser T, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020; 6(2):e001332. doi:10.1136/rmdopen-2020-001332 Go to original source... Go to PubMed...
  10. Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-1598. https://doi.org/10.1007/s00296-020-04676-4 Go to original source... Go to PubMed...
  11. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. http://dx.doi.org/10.1136/annrheumdis-2020-217871 Go to original source... Go to PubMed...
  12. Xu C, Yi Z, Cai R, et al. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev. 2021;20(4):102778. doi:10.1016/j.autrev.2021.102778. Go to original source... Go to PubMed...
  13. Esatoglu SN, Tascilar K, Babaoğlu H, et al. COVID-19 Among Patients with Inflammatory Rheumatic Diseases. Front Immunol. 2021;12:651715. Published 2021 Apr 16. doi:10.3389/fimmu.2021.651715. Go to original source... Go to PubMed...
  14. Darweesh O, Abdulrazzaq GM, Al-Zidan RN, et al. Evaluation of the Pharmacologic Treatment of COVID-19 Pandemic in Iraq. Current Pharmacology Reports. 2021 Aug 5:1-8. Go to original source... Go to PubMed...
  15. Sood A, Galestanian A, Murthy V, et al. COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
  16. Quartuccio L, Valent F, Pasut E, et al. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint bone spine. 2020; 87:439-43. doi: 10.1016/j.jbspin.2020.05.003. Go to original source... Go to PubMed...
  17. Salvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020;79:986-8. doi: 10.1136/annrheumdis-2020-217903 Go to original source... Go to PubMed...
  18. Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol. 2020; doi: 10.1002/art.41388. Go to original source... Go to PubMed...
  19. Michelena X, Borrell H, Lopez-Corbeto M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50:564-70. doi: 10.1016/j.semarthrit.2020.05.001. Go to original source... Go to PubMed...
  20. Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020; doi: 10.1007/s10067-020-05334-7. Go to original source... Go to PubMed...
  21. Fredi M, Cavazzana I, Moschetti L, et al. Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020;2:e549-e56. doi: 10.1016/S2665-9913(20)30169-7. Go to original source... Go to PubMed...
  22. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020; doi: 10.1136/annrheumdis-2020-218296. Go to original source... Go to PubMed...
  23. Tartof SY, Qian L, Hong V, et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results from an Integrated Health Care Organization. Ann Intern Med. 2020;173(10):773-781. doi:10.7326/M20-3742 Go to original source... Go to PubMed...
  24. Anderson MR, Geleris J, Anderson DR, et al. Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection: A Retrospective Cohort Study. Ann Intern Med. 2020;173(10):782-790. doi:10.7326/M20-3214 Go to original source... Go to PubMed...
  25. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi:10.1111/obr.13128 Go to original source... Go to PubMed...
  26. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755-767. https://doi.org/10.1080/17476348.2018.1506331 Go to original source... Go to PubMed...
  27. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. 2014;12:77. https://doi.org/10.1186/1479-5876-12-77 Go to original source... Go to PubMed...
  28. Freites Nunez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; doi: 10.1136/annrheumdis-2020-217984. Go to original source... Go to PubMed...